Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction

New England Journal of Medicine

Volumn 327, Issue 4, 1992, Pages 248-254

  Lau, Joseph ^a,d   Antman, Elliott M ^b,e   Jimenez Silva, Jeanette ^a   Kupelnick, Bruce ^c   Mosteller, Frederick ^c,e   Chalmers, Thomas C ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FIBRINOLYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; LIDOCAINE; STREPTOKINASE; UROKINASE; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0026652019     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199207233270406     Document Type: Article

References (63)

1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71.
2. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450–5.
3. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224–33.
4. Thacker SB. Meta-analysis: a quantitative approach to research integration. JAMA 1988; 259: 1685–9.
5. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA 1992; 268: 240–8.
6. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–48.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177–88.
8. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; 8: 141–51.
9. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162–73.
10. Robins JM, Greenland S, Breslow NE. A general estimator for the variance of the MantelHaenszel odds ratio. Am J Epidemiol 1986; 124: 719–23.
11. Lau J, Chalmers TC, Mosteller F. A comparison of statistical methods of pooling randomized control trials: an assessment of 45+ meta-analyses. Controlled Clin Trials (in press).
12. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260: 2088–93.
13. Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH. Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982; 307: 1180–2.
14. Furberg CD. Clinical value of intracoronary streptokinase. Am J Cardiol 1984; 53: 626–7.
15. Marder VJ, Francis CW. Thrombolytic therapy for acute transmural myocardial infarction: intracoronary versus intravenous. Am J Med 1984; 77: 921–8.
16. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556–85.
17. Patel B, Kloner RA. Analysis of reported randomized trials of streptokinase therapy for acute myocardial infarction in the 1980s. Am J Cardiol 1987; 59: 501–4.
18. Chalmers TC, Levin HR, Sacks HS, Reitman D, Berrier J, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. I. Control of bias and comparison with large Cooperative trials. Stat Med 1987; 6: 315–28.
19. Topol EJ. Acute myocardial infarction: treatment with thrombolytic therapy. Cardiol Clin 1989; 7: 827–36.
20. Naylor CD, Jaglal SB. Impact of intravenous thrombolysis on short-term coronary revascularization rates: a meta-analysis. JAMA 1990; 264: 697–702.
21. Held PH, Teo KK, Yusuf S. Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction. Circulation 1990; 82: 1668–74.
22. Honan MB, Harrell FE Jr, Reimer KA, et al. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990; 16: 359–67.
23. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988; 1: 1088–92.
24. Long-term and short-term beta-blockade after myocardial infarction. Lancet 1982; 1: 1159–61.
25. Yusuf S. The use of beta-blockers in the acute phase of myocardial infarction. In: Califf RM, Wagner GS, eds. Acute coronary care 1986. Boston: Martinus Nijhoff, 1985:73–88.
26. Chalmers TC, Berrier J, Sacks HS, Levin H, Reitman D, Nagalingam R. Meta-analysis of clinical trials as a scientific discipline. II. Replicate variability and comparison of studies that agree and disagree. Stat Med 1987; 6: 733–44.
27. Chalmers TC, Matta RJ, Smith H Jr, Kunzler A-M. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977; 297: 1091–6.
28. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
29. MacMahon S, Yusuf S. Effects of lidocaine on ventricular fibrillation, asystole, and early death in patients with suspected acute myocardial infarction. In: Califf RM, Wagner GS, eds. Acute coronary care 1987. Boston: Martinus Nijhoff, 1987:51–60.
30. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA 1988; 260: 1910–6.
31. Hine LK, Laird N, Hewitt P, Chalmers TC. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989; 149: 2694–8.
32. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–92.
33. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499–503.
34. Baber NS, Lewis JA. Confidence in results of beta-blocker postinfarction trials. BMJ 1982; 284: 1749–50.
35. Lewis JA. Beta-blockade after myocardial infarction — a statistical view. Br J Clin Pharmacol 1982; 14: Suppl: 15S–21S.
36. Lewis JA, Ellis SH. A statistical appraisal of postinfarction beta-blockers trials. Prim Cardiol 1982; Suppl 1: 31–7.
37. May GS, Eberlein KA, Furberg CD, Passamani ER, DeMets DL. Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 1982; 24: 331–52.
38. Baber NS, Lewis JA. Beta-adrenoceptor blockade and myocardial infarction: when should treatment start and for how long should it continue? Circulation 1983; 67: I-71—I-77.
39. Furberg CD, Bell RL. Effect of beta-blocker therapy on recurrent nonfatal myocardial infarction. Circulation 1983; 67: Suppl I: I-83—I-85.
40. Loeliger EA. Oral anticoagulation in the secondary prevention of myocardial infarction. Acta Med Scand Suppl 1981; 651: 305–15.
41. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction: a new approach to old data. Eur J Clin Pharmacol 1983; 24: 333–6.
42. Kaplan K. Prophylactic anticoagulation following acute myocardial infarction. Arch Intern Med 1986; 146: 593–7.
43. Aspirin after myocardial infarction. Lancet 1980; 1: 1172–3.
44. Canner PL. Aspirin in coronary heart disease: comparison of six clinical trials. Isr J Med Sci 1983; 19: 413–23.
45. Canner. An overview of six clinical trials of aspirin in coronary heart disease. Stat Med 1987; 6: 255–67.
46. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31.
47. Erkelens DW. Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia. Cardiology 1990; 77: Suppl 4: 33–8.
48. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916–24.
49. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1112–9.
50. O'Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234–44.
51. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988; 260: 945–50.
52. Hine LK, Laird NM, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989; 262: 3037–40.
53. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISST). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402.
54. The Aspirin Myocardial Infarction Study Research Group. The Aspirin Myocardial Infarction Study: final results. Circulation 1980; 62: Suppl V: V-79—V-84.
55. Chalmers TC. Problems induced by meta-analyses. Stat Med 1991; 10: 971–80.
56. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trials (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295–7.
57. Armitage P. Inference and decision in clinical trials. J Clin Epidemiol 1989; 42: 293–9.
58. Rosenthal R. The “file drawer problem” and tolerance for null results. Psychol Bull 1979; 86: 638–41.
59. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Controlled Clin Trials 1987; 8: 343–53.
60. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc [A] 1988; 151: 419–63.
61. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992; 45: 235–65.
62. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of the possible relation of treatment differences to quality scores in controlled randomized clinical trials. Controlled Clin Trials 1990; 11: 339–52.
63. Chalmers I, ed. Oxford database of perinatal trials. Version 1.2. Disk issue 6. Oxford, England: Oxford University Press, August 1991.